Astellas Oncology is committed to elevating the standard of cancer care. We focus on developing innovative, targeted therapies for hard-to-treat cancers with limited treatment options, which is where we see the greatest opportunity to help people living with cancer.
Our pipeline is strong, and the thoughtful collaborations that support it are stronger. To date, we’ve worked together with colleagues across the globe to introduce treatments in advanced prostate cancer, acute myeloid leukemia, and urothelial cancer. Now, we’re leveraging these collaborations to develop and test novel assets for gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, renal cell carcinoma, testicular cancer, and more.
Patients are at the heart of everything we do. We focus our efforts where their need is greatest, pushing the boundaries of possibility to deliver treatment and support aimed at improving the lives of patients and caregivers.
It’s an exciting time at Astellas Oncology, where our culture has never been more collaborative. We encourage our employees to think boldly and differently to make every day better for those impacted by cancer.
Astellas Oncology is committed to addressing the complexities of the cancer care journey by fueling the best ideas in cancer care beyond medicine. Our annual C3 Prize was established to spark innovation in cancer care for people with cancer, caregivers, and their loved ones.
Browse through the latest Astellas Oncology news and press releases, stay connected on social media, and contact our internal media team.
You are now leaving www.astellasoncology.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
